Xikang cooperates with afinita biotech to develop new anti-cancer monoclonal antibody drugs

Xikang (Cayman) Holding Co., Ltd (Emerging Stock Code: 6540) announced that its subsidiary Xikang biotechnology signed a commissioned development and manufacturing contract with afinita biotech of the United States, and will cooperate to develop new anti-cancer monoclonal antibody drugs of afinita biotech JHL logo high resolution estimates that the total value of the contract will be nearly 20 million US dollars by 2020 Xikang will provide cell line development, process development, mass production and other professional technologies for afinita biotech anti-cancer monoclonal antibody new drugs with its plant facilities in Zhubei, Taiwan and Wuhan, China About afinita biotechnology located in San Francisco, California, USA, founded in 2015 by a group of industry experts; afinita biotechnology focuses on the research and development of new anti-cancer drugs based on target therapy and immunotherapy About Xikang Xikang, founded by a group of senior people with rich R & D and production experience in the field of biotechnology, supported by several top-level venture capital, including Kleiner Perkins Caufield & Byers, Sequoia Capital, biomark capital, milestone capital, fidelity and China Development Industrial Bank, etc Hikvision's mission is to provide affordable world-class drugs for more patients around the world Xikang has built a world-class biopharmaceutical factory that meets the cGMP standards of the United States, the European Union and the International Coordination Conference (ICH) and local standards Xikang biological Taiwan R & D center supports the R & D work in preclinical and early clinical stages of similar biological drugs; Xikang biological Wuhan pharmaceutical factory will support the commercial production of biological drugs, which also enables Xikang biological to have a unique production capacity, enable it to produce its own products, and also provide contract processing services for specific customers For more information, please visit our website